Trial Profile
A phase I trial of AAD 2004 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2016
Price :
$35
*
At a glance
- Drugs Crisdesalazine (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GNT Pharma
- 30 Aug 2010 Treatment has been successfully completed in the first two cohorts, according to a Neurotech Pharmaceuticals media release.
- 30 Aug 2010 New trial record